Lurasidone

• Description:

  Lurasidone (SM-13496) is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM.

• Product Name Alternative:

  SM-13496

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  5-HT Receptor; Dopamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Lurasidone.html

• Purity:

  99.36

• Solubility:

  DMSO : 20.83 mg/mL (ultrasonic) |Ethanol : 3.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C ([C@H]1[C@H]2C[C@H] (CC2) [C@@H]31) N (C[C@H] (CCCC4) [C@@H]4CN5CCN (CC5) C6=NSC7=CC=CC=C67) C3=O

• Molecular Formula:

  C28H36N4O2S

• Molecular Weight:

  492.68

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Ishibashi T, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334 (1) :171-81.|[2]Sakine Atila Karaca, et al. Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals. Marmara Pharm J. 2017;21 (4) : 931-937.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  5-HT1 Receptor;5-HT7 Receptor; D2 Receptor; mLAG-3; MUC3

• Citation 01:

  Antibiotics (Basel) . 2024 Mar 28;13 (4) :308.|bioRxiv. 2024 Jan 14.|bioRxiv. 2025 Sep 9.|J Med Chem. 2024 Apr 25;67 (8) :6144-6188.|J Ocul Pharmacol Ther. 2024 Oct;40 (8) :536-542.|Marmara Pharm J. 2017;21 (4) : 931-937.|Marmara Pharm J. 2017;21 (4) : 931-937.|Nat Immunol. 2025 May;26 (5) :722-736.|Nature. 2023 Dec;624 (7992) :672-681.|ACS Chem Neurosci. 2020 Jan 15;11 (2) :173-183.|Marmara Pharm J. 2017;21 (4) : 931-937.|Physiol Behav. 2026 Feb:304:115176.

• CAS Number:

  367514-87-2